Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin

Summary

This is an open-label Phase I study of plasma, genitourinary, rectal, and pharyngeal pharmacokinetics of a single 1000mg oral dose of solithromycin. Study Objectives: The primary objective is to determine the pharmacokinetics of solithromycin in plasma, vaginal, cervical, seminal, rectal, and pharyngeal fluid samples after a single 1000mg oral dose.

Timeline

Start

2015-05-05

Primary completion

2017-01-13

Completion

2017-01-13

Drugs

Indications